GenSight Biologics

leading the use of gene therapy against blindness

Headquarters

Paris, France
Founders & Team

Bernard Gilly, Botond Roska, Jose Alain Sahel, Luk Vandenberghe, Serge Picaud
Year Founded

2012
Company type

Public company
Stock Ticker

EPA:SIGHT
Funding stage

IPO
Total funding ($M)

153
Investors

Invus, Arix Bioscience, Sofinnova Partners, Kreos Capital

Aging Target

Mitochondrial dysfunction
Disease indication

Leber Hereditary Optic Neuropathy (LHON), Retinitis Pigmentosa, Geographic Atrophy, Dry Age-related Macular Degeneration
Product modality

gene therapy
Clinical stage

Phase 3 Trials
Product names

GS010, GS011, GS030

GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.